| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-125 |
Sentence |
denotes |
VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo. |
| T1 |
0-125 |
Sentence |
denotes |
VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo. |
| TextSentencer_T2 |
126-202 |
Sentence |
denotes |
Angiogenesis is largely driven by vascular endothelial growth factor (VEGF). |
| T2 |
126-202 |
Sentence |
denotes |
Angiogenesis is largely driven by vascular endothelial growth factor (VEGF). |
| TextSentencer_T3 |
203-341 |
Sentence |
denotes |
However, the role of lipid second messengers such as lactosylceramide (LacCer) and LacCer synthase in angiogenesis is not well understood. |
| T3 |
203-341 |
Sentence |
denotes |
However, the role of lipid second messengers such as lactosylceramide (LacCer) and LacCer synthase in angiogenesis is not well understood. |
| TextSentencer_T4 |
342-474 |
Sentence |
denotes |
We have determined the distribution of various LacCer synthase mRNA transcripts using sequential analysis of gene expression (SAGE). |
| T4 |
342-474 |
Sentence |
denotes |
We have determined the distribution of various LacCer synthase mRNA transcripts using sequential analysis of gene expression (SAGE). |
| TextSentencer_T5 |
475-644 |
Sentence |
denotes |
Endothelial cells from colon cancer tissues had a 4.5-fold increase in a LacCer synthase transcript (beta1,4GalT-V) as compared to normal colon tissue endothelial cells. |
| T5 |
475-644 |
Sentence |
denotes |
Endothelial cells from colon cancer tissues had a 4.5-fold increase in a LacCer synthase transcript (beta1,4GalT-V) as compared to normal colon tissue endothelial cells. |
| TextSentencer_T6 |
645-778 |
Sentence |
denotes |
Consequently, our focus turned to understanding the role of this enzyme in regulating VEGF-induced angiogenesis in vitro and in vivo. |
| T6 |
645-778 |
Sentence |
denotes |
Consequently, our focus turned to understanding the role of this enzyme in regulating VEGF-induced angiogenesis in vitro and in vivo. |
| TextSentencer_T7 |
779-1056 |
Sentence |
denotes |
Herein, we show that in human endothelial cells, VEGF-induced angiogenesis is mitigated by dimethylsphingosine and suramin; inhibitors of sphingosine kinase 1(SphK-1) and sphingosine1-phosphate receptor 1(S1P (1)), respectively, and this were bypassed by LacCer but not by S1P. |
| T7 |
779-1056 |
Sentence |
denotes |
Herein, we show that in human endothelial cells, VEGF-induced angiogenesis is mitigated by dimethylsphingosine and suramin; inhibitors of sphingosine kinase 1(SphK-1) and sphingosine1-phosphate receptor 1(S1P (1)), respectively, and this were bypassed by LacCer but not by S1P. |
| TextSentencer_T8 |
1057-1295 |
Sentence |
denotes |
VEGF and basic fibroblast growth factor-induced angiogenesis was mitigated by PDMP; an inhibitor of glucosylceramide synthase and LacCer synthase in human umbilical vein endothelial cells (HUVEC) and human aortic endothelial cells (HAEC). |
| T8 |
1057-1295 |
Sentence |
denotes |
VEGF and basic fibroblast growth factor-induced angiogenesis was mitigated by PDMP; an inhibitor of glucosylceramide synthase and LacCer synthase in human umbilical vein endothelial cells (HUVEC) and human aortic endothelial cells (HAEC). |
| TextSentencer_T9 |
1296-1394 |
Sentence |
denotes |
Likewise, GalT-V gene ablation using corresponding siRNA also mitigated VEGF-induced angiogenesis. |
| T9 |
1296-1394 |
Sentence |
denotes |
Likewise, GalT-V gene ablation using corresponding siRNA also mitigated VEGF-induced angiogenesis. |
| TextSentencer_T10 |
1395-1545 |
Sentence |
denotes |
In Matrigel plug angiogenesis assay in nude mice, angiogenesis was markedly inhibited by D-PDMP with concordantly diminished LacCer synthase activity. |
| T10 |
1395-1545 |
Sentence |
denotes |
In Matrigel plug angiogenesis assay in nude mice, angiogenesis was markedly inhibited by D-PDMP with concordantly diminished LacCer synthase activity. |
| TextSentencer_T11 |
1546-1817 |
Sentence |
denotes |
Mechanistic studies revealed that the use of LY294002, a PI3 kinase inhibitor, mitigated VEGF-induced expression of platelet-endothelial cell adhesion molecule (PECAM-1/CD31); the trans-endothelial migration of a monocyte cell line (U-937) and angiogenesis in HAEC cells. |
| T11 |
1546-1817 |
Sentence |
denotes |
Mechanistic studies revealed that the use of LY294002, a PI3 kinase inhibitor, mitigated VEGF-induced expression of platelet-endothelial cell adhesion molecule (PECAM-1/CD31); the trans-endothelial migration of a monocyte cell line (U-937) and angiogenesis in HAEC cells. |
| TextSentencer_T12 |
1818-2047 |
Sentence |
denotes |
Since this enzyme is a target for VEGF action and LacCer serves as a lipid second messenger in inducing angiogenesis in vitro and in vivo, novel therapeutic approaches may be developed using our findings to mitigate colon cancer. |
| T12 |
1818-2047 |
Sentence |
denotes |
Since this enzyme is a target for VEGF action and LacCer serves as a lipid second messenger in inducing angiogenesis in vitro and in vivo, novel therapeutic approaches may be developed using our findings to mitigate colon cancer. |